{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Ichnos+Sciences+SA",
    "query": {
      "sponsor": "Ichnos Sciences SA"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T19:51:14.686Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03568162",
      "title": "Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Moderate to Severe Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "ISB 830 - Part 1 Group 1",
          "type": "DRUG"
        },
        {
          "name": "ISB 830 - Part 1 Group 2",
          "type": "DRUG"
        },
        {
          "name": "ISB 830 - Part 1 Group 3",
          "type": "DRUG"
        },
        {
          "name": "Placebo - Part 1 Group 4",
          "type": "DRUG"
        },
        {
          "name": "ISB 830 - Part 2 Group 5",
          "type": "DRUG"
        },
        {
          "name": "Placebo - Part 2 Group 6",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ichnos Sciences SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 462,
      "start_date": "2018-05-31",
      "completion_date": "2021-08-03",
      "has_results": true,
      "last_update_posted_date": "2022-08-23",
      "last_synced_at": "2026-09-30T19:51:14.686Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Clovis, California • Rolling Hills Estates, California + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "Bridgeport",
          "state": "Connecticut"
        },
        {
          "city": "Danbury",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03568162"
    },
    {
      "nct_id": "NCT03309111",
      "title": "Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed/Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "ISB 1342",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ichnos Sciences SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2017-10-25",
      "completion_date": "2023-12-15",
      "has_results": false,
      "last_update_posted_date": "2024-06-13",
      "last_synced_at": "2026-09-30T19:51:14.686Z",
      "location_count": 9,
      "location_summary": "Denver, Colorado • Baltimore, Maryland • Rochester, Minnesota + 4 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03309111"
    },
    {
      "nct_id": "NCT02683928",
      "title": "To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "GBR 830",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ichnos Sciences SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2016-03",
      "completion_date": "2017-06",
      "has_results": true,
      "last_update_posted_date": "2020-05-18",
      "last_synced_at": "2026-09-30T19:51:14.686Z",
      "location_count": 12,
      "location_summary": "Rogers, Arkansas • Los Angeles, California • San Diego, California + 9 more",
      "locations": [
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02683928"
    },
    {
      "nct_id": "NCT05862012",
      "title": "Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed/Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "ISB 2001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ichnos Sciences SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2023-11-01",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-09-30T19:51:14.686Z",
      "location_count": 10,
      "location_summary": "Palo Alto, California • Miami, Florida • Atlanta, Georgia + 7 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05862012"
    },
    {
      "nct_id": "NCT02829372",
      "title": "Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2 Expressing Solid Tumours"
      ],
      "interventions": [
        {
          "name": "CD3/HER2 bispecific monoclonal antibody",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ichnos Sciences SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2016-05",
      "completion_date": "2019-05",
      "has_results": false,
      "last_update_posted_date": "2020-10-09",
      "last_synced_at": "2026-09-30T19:51:14.686Z",
      "location_count": 4,
      "location_summary": "Fairway, Kansas • Detroit, Michigan • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02829372"
    },
    {
      "nct_id": "NCT03983395",
      "title": "Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ISB 1302 250 ng/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ISB 1302 325 ng/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ISB 1302 escalating doses,1200 ng/kg D15,22",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ISB 1302 at the MTD and/or RP2D dose",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ichnos Sciences SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1,
      "start_date": "2020-04-08",
      "completion_date": "2020-07-24",
      "has_results": false,
      "last_update_posted_date": "2021-05-24",
      "last_synced_at": "2026-09-30T19:51:14.686Z",
      "location_count": 5,
      "location_summary": "Gilbert, Arizona • Los Angeles, California • Louisville, Kentucky + 2 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03983395"
    },
    {
      "nct_id": "NCT05427812",
      "title": "Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed/Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "ISB 1442 SC injection escalating doses",
          "type": "DRUG"
        },
        {
          "name": "ISB 1442 SC injection at RP2D",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ichnos Sciences SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2022-09-27",
      "completion_date": "2024-11-19",
      "has_results": false,
      "last_update_posted_date": "2025-01-17",
      "last_synced_at": "2026-09-30T19:51:14.686Z",
      "location_count": 6,
      "location_summary": "Miami, Florida • Chicago, Illinois • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05427812"
    }
  ]
}